
    
      This is a multicenter, double-blind, randomized, controlled, roll-over retreatment clinical
      study of retreatment of subjects seeking lip augmentation who received treatment with either
      PN40082 or Restylane Silk in prior Protocol PRO 2018-02, and PN40082 in prior Protocol PRO
      2018-03. Subjects meeting the inclusion/exclusion criteria will receive a single additional
      treatment with either RV001, RV001 with a topical anesthetic, or PN40082. The Evaluating
      Investigator will be blinded to the treatment. Injections of the study device will be
      performed by an unblinded Treating Investigator.
    
  